---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-26-012266"
form_type: "8-K"
ticker: "SMTI"
cik: "0000714256"
company_name: "Sanara MedTech Inc."
filed_at: "2026-03-24T23:59:59+00:00"
generated_at: "2026-05-15T09:17:48.194057+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Sanara MedTech Q4 revenue $27.5M (+5% YoY); FY25 rev $103.1M (+19%); reaffirms FY26 guidance

## Summary
- Net revenue Q4 2025 $27.5M (+5% YoY); excluding $1.8M prior-year BIASURGE hurricane sales, growth was 13%.
- Full year 2025 net revenue $103.1M (+19% YoY); net loss from continuing ops narrowed to $0.4M from $1.9M.
- Adjusted EBITDA improved to $4.7M (Q4) and $17.0M (FY), vs $4.1M and $9.1M in prior year.
- Reaffirmed full year 2026 financial guidance; no specific numbers provided in the release.
- BIASURGE received Vizient Innovative Technology contract effective Jan 1, 2026.

## SEC filing metadata
- accession: 0001493152-26-012266
- form_type: 8-K
- ticker: SMTI
- cik: 0000714256
- company_name: Sanara MedTech Inc.
- filed_at: 2026-03-24T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/714256/000149315226012266/0001493152-26-012266-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/714256/000149315226012266/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-26-012266
- JSON: https://secwatch.observer/filing/0001493152-26-012266.json
- Plain text: https://secwatch.observer/filing/0001493152-26-012266.txt

## Key facts
- Earnings Releases
  Sanara MedTech Inc. reported the fourth quarter and full year ended December 31, 2025 results: revenue $27.5 million, net income Net loss from continuing operations of $1.1 million. Guidance reaffirmed.
  - Period: the fourth quarter and full year ended December 31, 2025
  - Revenue: $27.5 million
  - Net income: Net loss from continuing operations of $1.1 million
  - Guidance: reaffirmed
  - Result: reported results
  source text: December 31, 2025, and reaffirmed its financial guidance for the full year ending December 31, 2026. Fourth Quarter 2025 Financial Summary (1 ) ● Net revenue increased 5% to $27.5 million, compared to $26.3 million in the fourth quarter of 2024. ○ As previously disclosed, the Company experienced growth in sales of BIASURGE ® Advanced Surgical Solution
  evidence_url: https://www.sec.gov/Archives/edgar/data/714256/000149315226012266/0001493152-26-012266-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.